Hepatitis B, Hepatitis C
Conditions
Brief summary
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030. However, at present, the diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face. This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.
Detailed description
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. According to the survey, there are about 93 million chronic HBV infected people and 10 million chronic HCV infected people in China, accounting for 36.19% and 14.08% of the global HBV and HCV infected people respectively. Chronic HBV and HCV infection is the main cause of liver cirrhosis and liver cancer, which places a great burden on the national economy. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030, including 90% diagnosis rate, 80% treatment rate and 90% cure rate of viral hepatitis, in order to reduce 65% of viral hepatitis related deaths and reduce the disease burden. However, at present, the diagnosis rate of chronic HBV in China is 18.7%, the treatment rate is 10.8%, the diagnosis rate of chronic HCV is 30%, and the treatment rate is 9%, which are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face. This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.
Interventions
OTHERAnti-virus treatment
Anti-virus treatment
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* HBsAg/HBV DNA positive * or anti-HCV/HCV RNA positive
Exclusion criteria
* patients who refused to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epidemiological characteristics of hepatitis B and C | up to 192 weeks | Epidemiological characteristics of hepatitis B and C in Danzhou City, Hainan Province |
| Long-term outcome | up to 192 weeks | Long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province |
| Risk factors | up to 192 weeks | Risk factors for long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival rate for liver cancer | up to 192 weeks | Survival rate for liver cancer patients in Danzhou City, Hainan Province |
| Survival rate for cirrhosis | up to 192 weeks | Survival rate for cirrhosis patients in Danzhou City, Hainan Province |
| Incidence of cirrhosis | up to 192 weeks | Incidence of cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province |
| HBsAg loss | up to 192 weeks | The HBsAg loss rate of HBV infected patients in Danzhou City, Hainan Province |
| HBV interruption rate of perinatal transmission | up to 192 weeks | HBV interruption rate of perinatal transmission in Danzhou City, Hainan Province |
| Incidence of liver cancer | up to 192 weeks | ncidence of liver cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province |
| Hepatic decompensation | up to 192 weeks | Hepatic decompensation rate for HBV/HCV infected patients in Danzhou City, Hainan Province |
Contacts
Primary ContactJunfeng Chen, Dr.
Outcome results
None listed